CClinicalTrials.gg
CompletedNCT02614573INR-Cap piloteUpdated Nov 19, 2025

International Normalised Ratio Evaluation by Generalist Practitioners in Full-time Care Establishments for the Elderly

An interventional study of CoagucheckXSR Capillary INR measures in Aged and Nursing Homes, sponsored by Centre Hospitalier Universitaire de Nīmes. Completed at 1 site in France. Per ClinicalTrials.gov, last updated 2025-11-19.

Sponsored by Centre Hospitalier Universitaire de Nīmes · Not applicable, Interventional, and Diagnostic

Phase
Not applicable
Study type
Interventional
Enrollment
31
Allocation
Not applicable
Sex
All
01

Study summary

The main objective of this study is to evaluate, for a 6-month observation period, the concordance in terms of clinical decision making concerning therapeutic adjustment as determined by a weekly capillary International Normalised Ratio (INR) monitoring strategy versus the usual strategy in a population of dependent elderly people in nursing homes, treated with anti-vitamin K (AVK).

Read the detailed description

The secondary objectives of this study are to:

A. Estimate the intra-patient variability of capillary INR measures.

B. Estimate the time spent in the target INR (TTR) window of dependent elderly patients in nursing homes, under AVK treatment, and with a capillary INR monitoring strategy.

C. Estimate the number of venous thromboembolic events and bleeding events over the 6-month observation period.

02

Conditions studied

  • Aged
  • Nursing Homes

Keywords

  • Dependent
  • Aged, 80 and over
  • Aged
03

In context

Lead sponsor

Centre Hospitalier Universitaire de Nīmes is the lead sponsor of 587 studies on the registry; 96 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • The patient resides at the establishment for the dependent elderly (nursing home (EHPAD)) in Pont-Saint-Esprit, France
  • The patient must be insured or beneficiary of a health insurance plan
  • The patient treated with vitamin K antagonist for over six months
  • The patient must have given his/her informed and signed consent
  • For adults under guardianship, the legal guardian must have given free and informed consent and signed the consent

Exclusion criteria

Exclusion Criteria:

  • The patient is under judicial protection
  • The general practitioner in charge of the patient at the EHPAD does not want to participate in the study
  • It is impossible to correctly inform the patient, or his/her legal guardian
  • The patient, or his/her legal guardian, refuses to sign the consent
  • The patient is participating in another interventional study, or has participated in another interventional study within the past three months
  • The patient is in an exclusion period determined by a previous study
05

Study design

Phase
Not applicable
Primary purpose
Diagnostic
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
31 participants (actual)

Study arms

  • Experimental
    The study population

    The clinical phases of this study will be held in the nursing home (EHPAD; principal building + 2 annexes) of Pont-Saint-Esprit, located in France. Patients are elderly dependents treated by anti-vitamin K for more than 6 months.

    Device: CoagucheckXSR Capillary INR measures

Interventions

  • DeviceCoagucheckXSR Capillary INR measures

    We will be using the CoagucheckXSR device for capillary INR measures performed by nurses every 7 days during the 6 months of the study, plus after related intercurrent events. If capillary INR is \<2 or \>3 (with a tolerance of 1.9 to 3.1 given the margin of measurement inaccuracy of the coagulometer), then a classic venous measure is performed. If both tests agree, adaptation of treatment as indicated. If slightly discordant results, then the INR values are considered discordant and the decision to adjust the treatment dose and the next monitoring date for venous INR is made based on the value of the venous INR, according to the predefined protocol. If clinically significant discordance (\> 0.3), a venous INR is reperformed within 24 hours and if the discrepancy persists, dose adjustment is made according to the venous INR and the predefined protocol. If capillary INR is \> 4, then verification by venous measure and refer to general practitioner.

    Also known as: CoagucheckXSR

06

What researchers measure

Primary outcomes

  1. Is the capillary INR concordant with the venous INR ? yes/no

    Primary Outcome Measure as stated in protocol: Clinical concordances and clinical discrepancies between the capillary INR and venous INR every time they are concomitant

    Time frame: 6 months

Secondary outcomes

  1. The number of thromboembolic events per patient

    Time frame: 6 months

  2. The number of bleeding events per patient

    Time frame: 6 months

  3. The number of thromboembolic or bleeding events per patient

    Time frame: 6 months

  4. Coefficient of variation for capillary INR measures per patient

    Time frame: 6 months

  5. Time in therapeutique range (days)

    Time frame: 6 months

07

Study locations

1 site
  • EHPAD de l'Hôpital de Pont Saint Esprit
    Pont-Saint-Esprit, 30130, France
08

References and documents

Publications

  • Sikirdji C, Costa D, Alonso S, Clape JF, Amouyal M, de Waziere B, Fabbro-Peray P. Assessment of agreement and time in therapeutic range of capillary versus venous international normalised ratio in frail elderly people in a nursing home. Intern Med J. 2019 Nov;49(11):1442-1446. doi: 10.1111/imj.14626. PubMed 31713344 ↗

Individual participant data

Plan to share: No

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Nov 19, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02614573
Lead sponsor
Centre Hospitalier Universitaire de Nīmes
Responsible party
Sponsor
First posted
Nov 25, 2015
Start date
Feb 2016
Primary completion
Aug 13, 2016
Completion
Aug 13, 2016
Last update
Nov 19, 2025

Study contacts

Chloé Sikirdji, Interne
study director · Centre Hospitalier Universitaire de Nīmes
Jean-François Clape, MD
principal investigator · Centre Hospitalier Universitaire de Nīmes

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion